NCT06721299View on ClinicalTrials.gov

Clenbuterol to Target DUX4 in FSHD

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

July 31, 2028

Conditions
Muscular Dystrophy, Facioscapulohumeral
Interventions
DRUG

Clenbuterol

Beta-Agonist

Trial Locations (3)

14642

RECRUITING

University of Rochester Medical Center, Rochester

66160

RECRUITING

University of Kansas Medical Center, Kansas City

98104

RECRUITING

University of Washington, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

University of Rochester

OTHER

lead

Jeffrey Statland

OTHER